ResMedMEX:RMD 99 Pretax Margin % is 35.09% as of Mar. 2026, which is 38% above its 10-year median of 25.44. GuruFocus rates MEX:RMD with a GF Score™ of 99/100 and a GF Value™ of MXN5,059.75 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 818 Medical Devices & Instruments companies, ResMed ranks better than 95.97% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. ResMed's Pre-Tax Income for the
three
months ended in Mar. 2026 was MXN9,058 Mil. ResMed's Revenue for the
three
months ended in Mar. 2026 was MXN25,812 Mil. Therefore, ResMed's pretax margin for the quarter that ended in Mar. 2026 was 35.09%.
The historical rank and industry rank for ResMed's Pretax Margin % or its related term are showing as below:
MEX:RMD'
s Pretax Margin % Range Over the Past 10 Years
Min: 19.91 Med: 25.44 Max: 34.37
Current: 34.37
MEX:RMD's Pretax Margin % is ranked better than 95.97% of 818
companies
in the Medical Devices & Instruments industry
Industry Median: 2.505
vs MEX:RMD: 34.37
ResMed (MEX:RMD) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
ResMed Pretax Margin % Related Terms
ResMed Pretax Margin % Historical Data
* Premium members only.
The historical data trend for ResMed's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:RMD vs MDLN, WST, BDX: Pretax Margin % Comparison
For the Medical Instruments & Supplies subindustry, ResMed's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ResMed Pretax Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ResMed's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where ResMed's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ResMed (MEX:RMD) has a Pretax Margin % of 35.09% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on ResMed and its competitors. This is 38% above median its historical median of 25.44. Over the past decade, ResMed's Pretax Margin % has ranged from 19.91 to 34.37. According to the industry distribution chart, ResMed ranks #33 out of 818 companies in the Medical Devices & Instruments industry, placing it in the top 4%.
Is ResMed's Pretax Margin % too high?
ResMed's current Pretax Margin % of 35.09% is 38% above median its 10-year median of 25.44. Over the past 10 years, this metric has ranged from a low of 19.91 to a high of 34.37. The Medical Devices & Instruments industry median Pretax Margin % is 2.51. ResMed's value of 35.09% is 1300.8% above this industry median. Based on the distribution chart, ResMed ranks #33 out of 818 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, ResMed has a GF Score™ of 99/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ResMed's Pretax Margin % compare to MDLN and WST?
According to the Medical Devices & Instruments industry distribution chart, ResMed ranks #33 out of 818 companies for Pretax Margin %. This places ResMed in the top 4% of its industry — outperforming the majority of peers. The industry median Pretax Margin % is 2.51. ResMed's value of 35.09% is 1300.8% above this benchmark. Historically, ResMed's own Pretax Margin % has ranged from 19.91 to 34.37 over the past decade. While the company's 10-year median is 25.44 vs. the industry median of 2.51, ResMed has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Medical Devices & Instruments company?
The median Pretax Margin % among Medical Devices & Instruments companies is 2.51, based on 818 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ResMed's current Pretax Margin % of 35.09% is 1300.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on ResMed and its competitors. For the Medical Devices & Instruments industry, the median Pretax Margin % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ResMed's current Pretax Margin % is 35.09%, which is 38% above median its own 10-year median of 25.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ResMed stock overvalued right now?
Based on GuruFocus' analysis, ResMed (MEX:RMD) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN5,059.75, compared to a current price of MXN3,716.10 — trading 26.6% below its estimated fair value. The current Pretax Margin % is 35.09%, which is 38% above median its 10-year median of 25.44 and 1300.8% above the Medical Devices & Instruments industry median of 2.51. ResMed's overall GF Score™ is 99/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For ResMed (MEX:RMD), the current Pretax Margin % is 35.09% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ResMed (MEX:RMD) Overvalued in 2026?
Based on GuruFocus' analysis, ResMed stock appears to be undervalued.
The current stock price of MXN3,716.10 is trading 26.6% below its estimated GF Value™ of MXN5,059.75.
GuruFocus considers ResMed to be Modestly Undervalued.
Key valuation signals for MEX:RMD:
Pretax Margin %: 35.09% (38% above median its 10-year median of 25.44)
GF Value™: MXN5,059.75 vs. price of MXN3,716.10 (26.6% below fair value)
Industry Position: 1300.8% above the Medical Devices & Instruments median (#33 of 818)
No single metric tells the full story. See the MEX:RMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
99GF Score
Get the complete analysis for MEX:RMD
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:RMD has been successfully added to your 
